Quantcast
Last updated on April 16, 2014 at 16:55 EDT

Latest Catheter ablation Stories

2010-04-21 07:48:00

WALTHAM, Mass., April 21 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, specialty radiofrequency catheters will drive growth in the European catheter market and support the use of catheter ablation as a treatment for atrial fibrillation. According to MRG's new European Markets for Electrophysiology Mapping and Ablation Devices 2010 report, specialty radiofrequency ablation catheter use will grow at a compound...

2010-04-08 12:30:00

WATERLOO, Belgium, April 8, 2010 /PRNewswire/ -- Biosense Webster announces that this week it has obtained its first Ethics Committee approval for the CLARITY study, comparing the 1-year efficacy, safety and efficiency of CARTO(R) 3 System-guided radiofrequency ablation using the NAVISTAR(R) THERMOCOOL(R) Catheter versus fluoroscopy-guided radiofrequency ablation using the Pulmonary Vein Ablation Catheter(R) (PVAC(R), Ablation Frontiers, Medtronic) in patients with paroxysmal atrial...

2010-04-08 09:00:00

WATERLOO, Belgium/>, April 8, 2010/> /PRNewswire/ -- Biosense Webster announces that this week it has obtained its first Ethics Committee approval for the CLARITY study, comparing the 1-year efficacy, safety and efficiency of CARTO(R) 3 System-guided radiofrequency ablation using the NAVISTAR(R) THERMOCOOL(R) Catheter versus fluoroscopy-guided radiofrequency ablation using the Pulmonary Vein Ablation Catheter(R) (PVAC(R), Ablation Frontiers, Medtronic) in patients with paroxysmal atrial...

2010-03-11 10:50:00

WASHINGTON, March 11 /PRNewswire/ -- As reported in today's Wall Street Journal, the more than 2 million Americans with atrial fibrillation are now on notice that the over-zealous marketing tactics and incentives by manufacturers of expensive medical devices which are not approved by the U.S. Food and Drug Administration (FDA) for the treatment of atrial fibrillation are likely to be influencing doctors' and hospitals' decisions about treatment for their patients' heart conditions....

2010-02-21 13:15:12

Gene associated with atrial fibrillation in younger patients without known risk factors An international research team has identified a common gene variant associated with a form of the irregular heartbeat called atrial fibrillation. In their report in the journal Nature Genetics, being published online, the investigators describe finding that variations affecting a protein that may help control the heart's electrical activity appear to increase the risk of what is called lone atrial...

2010-01-26 16:01:45

Catheter treatment works dramatically better than drugs for common heart rhythm disorder Treating a common heart rhythm disorder by burning heart tissue with a catheter works dramatically better than drug treatments, according to a landmark study published in the Jan. 27 issue of the Journal of the American Medical Association (JAMA). One year after undergoing a treatment called catheter ablation, 66 percent of patients with an irregular heartbeat called atrial fibrillation (A-Fib) were free...

2010-01-26 15:48:08

Use of catheter ablation, in which radiofrequency energy is emitted from a catheter to eliminate the source of an irregular heartbeat, resulted in significantly better outcomes in patients with paroxysmal atrial fibrillation (intermittent cardiac rhythm disturbance) who had not responded previously to antiarrhythmic drug therapy, according to a study in the January 27 issue of JAMA. Atrial fibrillation (AF) represents an important public health problem, with patients having an increased...

2010-01-11 07:30:00

LAGUNA BEACH, California, January 11 /PRNewswire/ -- Advanced Cardiac Therapeutics, Inc. ("ACT"), a developer of advanced irrigated cardiac ablation systems, announced today that it has completed a $5 million 'Series B' equity financing. The financing was led by NBGI Ventures, a venture capital firm specialized in medical technology investments, and is expected to fund commercialisation in Europe. ACT was founded in 2007 to develop a novel irrigated radiofrequency cardiac ablation...

2009-12-01 07:41:00

MORRISVILLE, N.C., Dec. 1 /PRNewswire/ -- nContact Surgical, Inc. ("nContact"), a leader in the investigation of devices for minimally-invasive treatment for heart conditions, today announced the initiation of a feasibility clinical trial designed to evaluate the safety and efficacy of a combined surgical and catheter procedure, the convergent procedure, for the treatment of symptomatic paroxysmal atrial fibrillation (AF). This prospective, feasibility study will enroll patients at study...

2009-11-04 17:09:00

WASHINGTON, Nov. 4 /PRNewswire/ -- Sanford Wittels & Heisler, LLP, along with co-counsel Grant Morris, announced today that AtriCure, Inc., a medical device company specializing in cardiac surgical ablation systems, has reached a tentative settlement agreement with the Department of Justice (DOJ) in a qui tam case filed in 2007 for $3.8 million plus interest over a five-year period. Sanford Wittels & Heisler and Grant Morris represent the relator in the case against AtriCure, which...